Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 46 entries
View as:

A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

Phase: N/A Priority: Normal
NCT ID: NCT03548220 Org: User:
Start: 08/09/18 End: 10/09/20 Due: 10/09/21

Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT03991312 Org: User:
Start: 06/20/19 End: 09/10/19 Due: 09/10/20

A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

Phase: N/A Priority: Normal
NCT ID: NCT03559699 Org: User:
Start: 06/26/18 End: 11/12/20 Due: 11/12/21

Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)

Phase: N/A Priority: Normal
NCT ID: NCT04964323 Org: User:
Start: 07/02/21 End: 06/30/23 Due: 06/30/24

A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06745271 Org: User:
Start: 12/20/24 End: 02/21/25 Due: 02/21/26

A Phase I Study of AG-348 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02149966 Org: User:
Start: 05/31/14 End: 11/30/14 Due: 11/30/15

A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881

Phase: N/A Priority: Normal
NCT ID: NCT03960502 Org: User:
Start: 05/16/19 End: 09/07/19 Due: 09/07/20

A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348

Phase: N/A Priority: Normal
NCT ID: NCT03703505 Org: User:
Start: 05/24/18 End: 06/04/18 Due: 06/04/19

A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT03282513 Org: User:
Start: 09/26/17 End: 03/31/18 Due: 03/31/19

A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03834584 Org: User:
Start: 05/24/19 End: 06/17/20 Due: 06/17/21

Single and Multiple Ascending Dose Study and Food Effect Study for AG181

Phase: N/A Priority: Normal
NCT ID: NCT06286033 Org: User:
Start: 02/20/24 End: 10/01/25 Due: 10/01/26

Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008

Phase: N/A Priority: Normal
NCT ID: NCT04995315 Org: User:
Start: 07/02/21 End: 09/22/23 Due: 09/22/24

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT05610657 Org: User:
Start: 01/10/23 End: 07/21/23 Due: 07/21/24

A Safety and Tolerability Study of AG-519 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02630927 Org: User:
Start: 12/31/15 End: 12/31/16 Due: 12/31/17

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period

Phase: N/A Priority: Normal
NCT ID: NCT05144256 Org: User:
Start: 06/08/22 End: 06/30/29 Due: 06/30/30

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

Phase: N/A Priority: Normal
NCT ID: NCT05031780 Org: User:
Start: 02/11/22 End: 02/28/30 Due: 02/28/31

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

Phase: N/A Priority: Normal
NCT ID: NCT04770753 Org: User:
Start: 12/20/21 End: 12/31/28 Due: 12/31/29

A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy

Phase: N/A Priority: Normal
NCT ID: NCT06286046 Org: User:
Start: 03/31/26 End: 12/31/28 Due: 12/31/29

A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study

Phase: N/A Priority: Normal
NCT ID: NCT05777993 Org: User:
Start: 07/06/23 End: 08/31/29 Due: 08/31/30

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

Phase: N/A Priority: Normal
NCT ID: NCT04770779 Org: User:
Start: 11/30/21 End: 06/30/29 Due: 06/30/30

A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia

Phase: N/A Priority: Normal
NCT ID: NCT03692052 Org: User:
Start: 03/20/19 End: 09/30/30 Due: 09/30/31

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Phase: N/A Priority: Normal
NCT ID: NCT05490446 Org: User:
Start: 11/07/22 End: 11/30/28 Due: 11/30/29

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period

Phase: N/A Priority: Normal
NCT ID: NCT05175105 Org: User:
Start: 06/06/22 End: 01/31/30 Due: 01/31/31

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

Phase: N/A Priority: Normal
NCT ID: NCT06924970 Org: User:
Start: 05/01/25 End: 05/31/27 Due: 05/31/28

Pyruvate Kinase Deficiency Global Longitudinal Registry

Phase: N/A Priority: Normal
NCT ID: NCT03481738 Org: User:
Start: 04/23/18 End: 05/31/27 Due: 05/31/28